Pluristem Therapeutics Inc. (Nasdaq:PSTI) is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products , derived from human placenta, for the treatment of several severe ischemic and autoimmune disorders.

19 November 2009
Pluristem Therapeutics Presents Three Month Follow-Up Data from First Patient to Receive Placental Derived PLX-PAD at Two Meetings in Germany and France
Presentations also Address the Strategic Partnerships in the Life Science Industry and the Development of PLX Cells for the Treatment of Intestinal Disease

---

17 November 2009
Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD
Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured Efficacy Parameters

---

20 October 2009
Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at the World Conference on Regenerative Medicine

---

14 October 2009
Pluristem Therapeutics Will Present at the New England-Israel Life Sciences Summit

---

06 October 2009
Pluristem Therapeutics to Raise $3.0 Million in Registered Direct Offering

---

29 September 2009
Pluristem Therapeutics Has Been Selected to Present at The Israeli Presidential Conference 2009: Facing Tomorrow, Based on the Company’s Proprietary Technology and the Potential to Shape The Future of the Stem Cell Industry

---

23 September 2009
Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease

---

10 September 2009
Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease

---

09 September 2009
Pluristem Therapeutics Will Present its Unique Placenta Derived Stem Cell Therapy Approach at Charles River Biotech Symposium

---

11 August 2009
Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in Critical Limb Ischemia at MSC2009 Regenerative Medicine and Adult Stem Cell Therapy Conference

---

04 August 2009
Pluristem’s Award from the Israeli Office of the Chief Scientist Increased to $2.3 Million

---

08 July 2009
Griffin Securities Initiates Independent Research Coverage on Pluristem Therapeutics Inc.

---

07 July 2009
Pluristem Therapeutics Announces First Patient Enrollment in Phase I Clinical Trial for Treatment of Peripheral Artery Disease With PLX-PAD

---

29 June 2009
Pluristem Therapeutics was Awarded a $1.9 Million Grant from the Office of the Chief Scientist in the Israeli Government

---

16 June 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Approval Paves Way for US and European Trials That Will Enroll Patients Diagnosed with Critical Limb Ischemia Who are Facing Amputation

---

10 June 2009
Pluristem Therapeutics to Present at the Second Annual Life Science Conference of The Society of Investment Professionals in Germany

---

8 June 2009
Pluristem Therapeutics to Present at the 8th Israel Life Science Industry (ILSI) BioMed Conference

---

2 June 2009
Stanford's Professor John Cooke Joins Pluristem's Scientific Advisory Board

---

26 May 2009
Pluristem Therapeutics to Present at the International Society for Stem Cell Research (ISSCR) 7th Annual Meeting

---

12 May 2009
Pluristem Therapeutics to Present at the Center for Finance Education

---

6 May 2009
Pluristem Therapeutics Announces $1.3 Million Securities Offering with Two Institutional Investors.
Healthcare fund to subscribe to the majority of the offering

---

5 May 2009
Pluristem Therapeutics Announces Major Clinical Site in North Carolina for PLX-PAD Phase-I Trial

---

5 May 2009
Pluristem Therapeutics to Present at the 2009 BIO International Convention as Part of the Israeli Delegation

---

28 April 2009
Pluristem Therapeutics to Present Its Clinical Path at the International Society for Cellular Therapy (ISCT) 15th Annual Meeting

---

20 April 2009
Pluristem Therapeutics to Present at the Tel-Aviv Stock Exchange

---

7 April 2009
Pluristem Therapeutics to Sponsor the World Conference on Regenerative Medicine

---

31 March 2009
Pluristem Therapeutics to Present at the German Equity Forum

---

17 March 2009
Pluristem Therapeutics to Present at “The Stem Cell Network” Conference

---

09 March 2009
Pluristem Therapeutics Prepares for Placental-Derived Stem Cell Clinical Trial

---

02 March 2009
Pluristem Therapeutics Receives FDA Clearance to Begin “First-In-Human” Placenta-Derived Stem Cell Clinical Trial

---

17 Feb 2009
Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells

---

11 Feb 2009
Pluristem Therapeutics Appoints Dr. Frida Grynspan to Vice President of Research and Development

---

11 Feb 2009
Pluristem Receives Deficiency and Compliance Notice from Nasdaq.
Company is Now in Compliance

---

02 Feb 2009
Pluristem Therapeutics’ cGMP Facilities Approved for Clinical Manufacturing in Europe

---

30 Jan 2009
Pluristem Therapeutics Announces US $1,200,000 Restricted Share Purchase

---

27 Jan 2009
Pluristem Therapeutics Collaborates with the Charité - Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital for its Clinical Trials in Germany

---

20 Jan 2009
Pluristem Therapeutics to Present at the 19th Israeli Medical Association World Fellowship International Conference

---

13 Jan 2009
Pluristem Therapeutics Files an IND Application with the FDA to Initiate a Phase I Clinical Trial Utilizing PLX-PAD for Critical Limb Ischemia

---

For more News